A recent Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis has now shown that aromatase inhibitors are also more effective than tamoxifen in premenopausal women with oestrogen receptor-positive (ER +) BC who received OFS [29]. Here, CYP19A1 is linked to breast cancer.